APA (7th ed.) Citation

C, L., HH, Y., CY, Z., SY, C., YS, L., BC, W., . . . JJ, Y. (2025). PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. Clinical lung cancer, 26(4), 263. https://doi.org/10.1016/j.cllc.2024.12.002

Chicago Style (17th ed.) Citation

C, Lu, et al. "PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease." Clinical Lung Cancer 26, no. 4 (2025): 263. https://doi.org/10.1016/j.cllc.2024.12.002.

MLA (9th ed.) Citation

C, Lu, et al. "PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease." Clinical Lung Cancer, vol. 26, no. 4, 2025, p. 263, https://doi.org/10.1016/j.cllc.2024.12.002.